KR890001572A - 표유동물에게 히알우론산을 원격 투여하는 방법 - Google Patents

표유동물에게 히알우론산을 원격 투여하는 방법 Download PDF

Info

Publication number
KR890001572A
KR890001572A KR870006850A KR870006850A KR890001572A KR 890001572 A KR890001572 A KR 890001572A KR 870006850 A KR870006850 A KR 870006850A KR 870006850 A KR870006850 A KR 870006850A KR 890001572 A KR890001572 A KR 890001572A
Authority
KR
South Korea
Prior art keywords
hyaluronic acid
less
administered
dosage
weight
Prior art date
Application number
KR870006850A
Other languages
English (en)
Other versions
KR950007233B1 (ko
Inventor
에이치.슐츠 리차드
에스.웰렌 테리
디.그린 나단
케이.브라운 카렌
오우.모지어 죤
Original Assignee
휄렉스 오트 할터
모베이 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 휄렉스 오트 할터, 모베이 코포레이션 filed Critical 휄렉스 오트 할터
Publication of KR890001572A publication Critical patent/KR890001572A/ko
Application granted granted Critical
Publication of KR950007233B1 publication Critical patent/KR950007233B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

포유동물에세 히알우론산을 원격 투여하는 방법.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 수근골 관절에 프로인트 완전 보조제로 유발된 외상을 갖는 처리 및 대조용 말에 히알우론산을 처리한 후의 경과 일수에 대한 수근골 관절 영역에서의 변화를 플롯팅한 것이다.
제2도는 제1도에서와 동일한 방식으로 동일한 말에 처리한 후의 경과일수에 대한 운동범위의 변화를 플롯팅 한 것이다.
제3도는 제1도에서와 동일한 방식으로 동일한 말에 처리한 후의 경과 일 수에 대한, 처리일로 정상화된 운동범위의 변화를 플롯팅한 것이다.

Claims (10)

  1. 히알우론산 또는 이의 약물학적으로 허용되는 염의 유효량을 자극된 조직으로부터 멀리 떨어져 있는 포유동물의 신체 부위에 또는 신체상의 투여함을 특징으로 하여, 자극된 포유동물 조직에서의 염증, 통증, 또는 외상의 다른 증상을 경감시키는 방법.
  2. 제1항에 있어서, 투여 용량을 국소, 피하, 근육내 또는 정맥내 투여하는 방법.
  3. 제1항에 있어서, 투여 용량이 치료될 대상의 체중 kg당 적어도 약 0.044mg인 방법.
  4. 제1항에 있어서, 투여 용량이 치료될 대상의 체중 kg당 적어도 0.088mg인 방법.
  5. 제1항에 있어서, 히알우론산을 37℃에서의 점도가 약 200C/S 미만인 0.5 내지 3.0중량%수용액으로 하여 주사 경로로 투여하는 방법.
  6. 제1항에 있어서, 히알우론산이, FPLC로 측정한 결과 거의 전적으로 1.5 내지 4×106달톤의 분자량 분포를 갖는 방법.
  7. 제1항에 있어서, 히알우론산이 비-발열성이며, UV 흡광도를 사용하여 측정한 결과 약 1.25mg/ml 미만의 아미노산과 단백질의 총 함량 및 약 0.06mg/ml 미만의 핵산 함량을 갖는 방법.
  8. 37℃에서의 용액 점도가 약 200C/S 미만이고 FPLC로 측정한 분자량 분포가 약 1.5 내지 4.0×106달톤의 단일 표시의 피크를 갖는 나트륨 히알우로네이트의 대량 1중량% 수용액을 말의 체중 kg당, 히알우로네이트로 적어도 약 0.088mg의 용량으로 근육내 주사함을 특징으로 하여, 말 관절의염증 또는 통증 또는 둘 다를 부분적으로 경감시키는 방법.
  9. 제2항에 있어서, 히알우론산을 경피용 담체와의 혼합물 형태로 국소적으로 투여하는 방법.
  10. 제9항에 있어서, 히알우로산이 약 0.5내지 3.0중량%의 수용액이며, 약 30용적%까지의 경피용 담체와 혼합하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870006850A 1986-04-28 1987-07-01 포유동물에게 히알우론산을 원격투여하는 방법 KR950007233B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US856,732 1986-04-28
US06/856,732 US4808576A (en) 1986-04-28 1986-04-28 Remote administration of hyaluronic acid to mammals

Publications (2)

Publication Number Publication Date
KR890001572A true KR890001572A (ko) 1989-03-27
KR950007233B1 KR950007233B1 (ko) 1995-07-07

Family

ID=25324378

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870006850A KR950007233B1 (ko) 1986-04-28 1987-07-01 포유동물에게 히알우론산을 원격투여하는 방법

Country Status (13)

Country Link
US (1) US4808576A (ko)
EP (1) EP0243867B1 (ko)
JP (1) JP2567393B2 (ko)
KR (1) KR950007233B1 (ko)
AT (1) ATE61523T1 (ko)
AU (1) AU596838B2 (ko)
CA (1) CA1314218C (ko)
DE (1) DE3768546D1 (ko)
DK (1) DK212587A (ko)
ES (1) ES2038135T3 (ko)
HU (1) HUT43790A (ko)
NZ (1) NZ220098A (ko)
ZA (1) ZA872964B (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030026384A (ko) * 2001-09-12 2003-04-03 정옥조 당뇨병 환자용 건강식품의 제조방법 및 그 제품
KR20230013655A (ko) * 2021-07-15 2023-01-27 최문석 짬뽕 감자 제조방법

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468737A (en) * 1982-05-07 1995-11-21 Carrington Laboratories, Inc. Wound healing accelerated by systemic administration of polysaccharide from aloe
US5080893A (en) * 1988-05-31 1992-01-14 University Of Florida Method for preventing surgical adhesions using a dilute solution of polymer
US5140016A (en) * 1988-05-31 1992-08-18 University Of Florida Method and composition for preventing surgical adhesions using a dilute solution of polymer
US6010692A (en) * 1988-05-31 2000-01-04 University Of Florida Research Foundation, Inc. Method and composition for preventing surgical adhesions and tissue damage
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5102783A (en) * 1990-01-12 1992-04-07 Vetrepharm, Inc. Composition and method for culturing and freezing cells and tissues
IT1240316B (it) * 1990-02-21 1993-12-07 Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. Composizioni a base di acido ialuronico ad alto peso molecolare somministrabili per via topica per il trattamento di infiammazioni del cavo orale ,per la cosmetica e l'igiene del cavo orale
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
DE69125595T2 (de) * 1990-10-18 1997-11-13 Shiseido Co Ltd Kombination von hyaluronsäure mit einem medizinischen bestandteil, und seine herstellung
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
JP3310994B2 (ja) * 1991-07-03 2002-08-05 電気化学工業株式会社 アレルギー治療剤
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6136793A (en) * 1992-02-20 2000-10-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US20050090662A1 (en) * 1997-01-15 2005-04-28 Beavers Ellington M. Method of making free acids from polysaccharide salts
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
DK1083929T3 (da) * 1998-06-05 2007-06-11 Nutramax Lab Inc Anvendelse af anabolske stoffer
JP4607264B2 (ja) * 1998-12-01 2011-01-05 生化学工業株式会社 ヒアルロン酸を有効成分とする異所性石灰化抑制剤
EP1165097B1 (en) * 1999-02-01 2007-05-02 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and their use
CA2366897C (en) * 1999-04-06 2009-11-17 Andrew B. Onderdonk Immunomodulatory compositions and methods of use thereof
NZ533078A (en) * 2000-07-31 2006-11-30 Dermal Res Lab Inc Preventing or treating diseases associated with allergies, autoimmunity and adhesion, metastatic and coronary cascades using complex carbohydrates, in particular hyaluronic acid
US7879824B2 (en) * 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
DE10053053A1 (de) * 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
DE10111165A1 (de) * 2001-03-02 2002-10-10 Knoell Hans Forschung Ev Verwendung von Hyaluronsäure-Uroniden zur Behandlung von entzündlichen Vorgängen
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
US6607745B2 (en) 2001-05-18 2003-08-19 Harry Leneau Ingestion of hyaluronic acid for improved joint function and health
US6528076B2 (en) 2001-07-06 2003-03-04 Magic Herb Corp. Topical compositions and methods for treating pain
WO2003070256A1 (en) * 2002-02-15 2003-08-28 Research Development Foundation Hyaluronic acid mediated adenoviral transduction
US20050142208A1 (en) * 2002-05-09 2005-06-30 Won Min Yoo Pharmceutical composition for treatment of wounds conntaining blood plasma or serum
JP2004135177A (ja) * 2002-10-11 2004-04-30 Sharp Corp 携帯電話機
US7485629B2 (en) * 2002-10-16 2009-02-03 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treatment of joint damage
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
NZ540045A (en) 2002-10-16 2008-04-30 Frank D Marcum Treatment for traumatic synovitis and damaged articular cartilage with chondroitin sulfate, N-acetyl D-glucosamine and hyaluronan
US20080003258A1 (en) * 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
ATE414522T1 (de) * 2003-10-09 2008-12-15 Robert John Petrella Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
GB0411165D0 (en) * 2004-05-19 2004-06-23 Bionovate Ltd Hyaluronic acid containing pharmaceutical or veterinary compounds
CA2475762A1 (en) * 2004-07-27 2006-01-27 Rycor Technology Investments Corp. Dose dependent elimination of ha and cell receptor stimulation
CA2590159C (en) * 2004-12-30 2011-07-12 Genzyme Corporation Regimens for intra-articular viscosupplementation
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
EP3028677A1 (en) 2005-12-14 2016-06-08 Anika Therapeutics Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
EP1968614A2 (en) 2005-12-14 2008-09-17 Anika Therapeutics Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US20080102107A1 (en) * 2005-12-16 2008-05-01 Valex Pharmaceuticals, Llc Compositions and methods for transdermal joint pain therapy
NZ575334A (en) * 2006-09-13 2012-03-30 Enhance Skin Products Inc Cosmetic composition for the treatment of skin and methods thereof
WO2008094910A2 (en) 2007-01-30 2008-08-07 Cypress Pharmaceutical, Inc. Hyaluronate compositions
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
US8178511B1 (en) * 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
CN102223858B (zh) 2008-10-02 2015-04-01 L.R.R.&D.有限公司 界面层伤口敷料
EP2886104A1 (en) 2013-12-11 2015-06-24 Patir, Suleyman An intra-articular gel

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055660A (en) * 1974-06-26 1977-10-25 Meierhenry Dwight W Treatment for warts
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
JPS56164120A (en) * 1980-05-22 1981-12-17 Chisso Corp Antitumor agent
IT1212892B (it) * 1983-10-11 1989-11-30 Della Valle Francesco Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
US4517295A (en) * 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
NO160722C (no) * 1983-11-25 1989-05-24 Miles Inc Fremgangsmaate for fremstilling av ultraren hyaluronsyre.
NO161573C (no) 1983-11-25 1989-08-30 Miles Inc Fremgangsmaate til fremstilling av hyaluronsyre.
US4716224A (en) * 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
JPS6120034A (ja) * 1984-07-06 1986-01-28 Konishiroku Photo Ind Co Ltd 写真乳剤の保管方法
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
GB8509301D0 (en) * 1985-04-11 1985-05-15 Clinical Products Dev Ltd Device for surgical procedures

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030026384A (ko) * 2001-09-12 2003-04-03 정옥조 당뇨병 환자용 건강식품의 제조방법 및 그 제품
KR20230013655A (ko) * 2021-07-15 2023-01-27 최문석 짬뽕 감자 제조방법

Also Published As

Publication number Publication date
KR950007233B1 (ko) 1995-07-07
JP2567393B2 (ja) 1996-12-25
EP0243867A2 (de) 1987-11-04
NZ220098A (en) 1991-06-25
HUT43790A (en) 1987-12-28
ATE61523T1 (de) 1991-03-15
ES2038135T3 (es) 1996-07-16
US4808576A (en) 1989-02-28
AU7178287A (en) 1987-10-29
ZA872964B (en) 1987-10-20
EP0243867A3 (en) 1988-03-23
JPS62255428A (ja) 1987-11-07
DK212587D0 (da) 1987-04-27
AU596838B2 (en) 1990-05-17
DE3768546D1 (de) 1991-04-18
CA1314218C (en) 1993-03-09
DK212587A (da) 1987-10-29
EP0243867B1 (de) 1991-03-13

Similar Documents

Publication Publication Date Title
KR890001572A (ko) 표유동물에게 히알우론산을 원격 투여하는 방법
Frost Diclofenac versus lidocaine as injection therapy in myofascial pain
KR950701818A (ko) 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
KR930003912A (ko) 울혈성 심장 마비 치료법
BR9608435A (pt) Metodo para medicação do sistema de controle inflatório e de reações inflamatórias adversas e para produção de composto para o tratamento da patologia de reações inflamatórias adversas.
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
DE69733089D1 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
KR900003205A (ko) 제약 화합물
ES2095086T3 (es) Metodo para el tratamiento y la prevencion de la obesidad.
BR9612355A (pt) Agentes de ligação com os receptores de ácido hialurÈnico e o uso destes.
US4624851A (en) Treatment of symptoms of neoplastic diseases
Borvendeg et al. Ovulation induced by synthetic luteinizing hormone releasing factor in androgen-sterilized female rats
KR930003913A (ko) 덱스트로메토르판의 진해효과를 증진시키기 위한 방법 및 약제학적 조성물
KR890007728A (ko) 진통제 제조방법
US4259322A (en) Method of treatment of tuberculosis
JPH01503542A (ja) Ｃｎｓ傷害における甲状腺刺激ホルモン放出ホルモン類似物
RU99122954A (ru) Пептидные фрагменты основного белка миелина, фармацевтические композиции на их основе и применение данных композиций для лечения рассеянного склероза
SILVETTE Mechanism of pentothal sodium antidiuresis
US4670418A (en) Method of using somatostatin as an analgesic or an anesthetic
MXPA01012663A (es) Uso de interleucina-11 para tratar el shock hemorragico.
KR940002268A (ko) 21-클로로-프레그난 유도체
RU96122371A (ru) Способ лечения эндогенных и послеоперационных увеитов
RU94027770A (ru) Препарат для профилактики и лечения гинекологических и послеродовых заболеваний самок сельскохозяйственных животных и способ его применения

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090618

Year of fee payment: 15

EXPY Expiration of term